SYBX - Synlogic, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.75
-0.65 (-4.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.40
Open13.48
Bid8.00 x 1100
Ask0.00 x 800
Day's Range12.64 - 14.00
52 Week Range7.27 - 22.40
Volume225,302
Avg. Volume165,546
Market Cap324.244M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.89
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.83
Trade prices are not sourced from all markets
  • Investor's Business Daily16 days ago

    How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease

    Rubius Therapeutics could rival BioMarin Pharmaceutical in treating a metabolic disorder but, first, the duo will face a dark horse candidate in the form of Synlogic.

  • Business Wire17 days ago

    Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)

    Synlogic, Inc., (Nasdaq:SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced positive interim clinical data from the healthy volunteer (HV) arm of its ongoing Phase 1/2a study of SYNB1618 in HVs and patients with PKU. The first part of this trial, which evaluated SYNB1618 versus placebo (PBO) in single- (SAD) and multiple-ascending dose (MAD) cohorts of HVs, successfully met the study’s primary objectives, to demonstrate safety and tolerability of SYNB1618 in HVs and to identify a suitable dose to evaluate in patients with PKU.

  • Business Wire23 days ago

    Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the H. C. Wainwright 20th Annual Global Investment Conference at 8:45 am ET on Wednesday, September 5, 2018, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Synlogic data shows reduction in disability-causing disease in mice
    American City Business Journalslast month

    Synlogic data shows reduction in disability-causing disease in mice

    A probiotic pill containing a beneficial strain of E.Coli could reduce the root problem of a hereditary disease that causes intellectual disabilities by 40 percent.

  • Business Wirelast month

    Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the publication of data from preclinical studies of SYNB1618, the Company’s Synthetic Biotic development program targeting PKU, in Nature Biotechnology. The data demonstrate that oral administration of SYNB1618 significantly reduced blood phenylalanine (Phe) levels, the key metabolite associated with PKU, in mouse models of PKU and resulted in dose-dependent pharmacodynamics in healthy non-human primates (NHPs).

  • Business Wirelast month

    Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates

    - Data from Phase 1/2 studies of SYNB1618 and SYNB1020 expected by end of 2018 –

  • Business Wirelast month

    Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the 2018 Wedbush PacGrow Healthcare Conference at 3:05pm ET on Tuesday, August 14, 2018, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Business Wire3 months ago

    Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018

    Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, announced the presentation of new preclinical data from its Synthetic Biotic medicine oncology program at the annual meeting of the Federation of Clinical Immunology Societies (FOCIS 2018) held June 20-23, in San Francisco, CA. The data demonstrate the breadth of the company’s platform to generate Synthetic Biotic medicines that secrete or consume immunologically relevant compounds for the potential treatment of cancer and inflammation. “These data highlight the plasticity of our Synthetic Biotic platform and its potential as a robust engine for the production and delivery of a variety of immunological payloads, which can have a profound effect on the tumor microenvironment and potential therapeutic use in immune-related conditions,” said Jose Lora, Ph.D., Synlogic’s vice president of research.

  • Business Wire3 months ago

    Synlogic Joins Russell 3000® Index

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the company’s addition to the Russell 3000® Index, following the Russell US Indices’ annual reconstitution, effective Monday, June 25, 2018. “We are pleased to benchmark Synlogic’s growth with our addition to the Russell 3000 Index, which offers a platform to increase the company’s visibility and exposure to leading institutional investors,” said Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer and chief medical officer. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indices.

  • Business Wire3 months ago

    Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

    Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced the presentation of preclinical data from SYNB1618, an investigational Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1/2a clinical trial in healthy volunteers and patients with PKU. The data demonstrate that oral administration of SYNB1618 resulted in lower blood Phe levels and a quantitative, dose-dependent production of biomarkers indicating SYNB1618-related activity in an animal model of PKU and healthy NHPs. “For patients with PKU, life-long disease management can be challenging due to the protein-restricted diet required to accompany currently available treatments.

  • Why Synlogic (SYBX) Could Be a Potential Winner
    Zacks4 months ago

    Why Synlogic (SYBX) Could Be a Potential Winner

    Synlogic (SYBX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

  • Business Wire4 months ago

    Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®

    Synlogic, Inc.  , a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, announced that new preclinical data from SYNB1020, a Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia, were presented at Digestive Disease Week , held June 2-5, ...

  • Synlogic (SYBX) Enters Oversold Territory
    Zacks4 months ago

    Synlogic (SYBX) Enters Oversold Territory

    Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

  • Business Wire4 months ago

    Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update

    Synlogic, Inc. , a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today reported its financial results for the first quarter ended March 31, 2018.

  • Business Wire4 months ago

    Synlogic Announces Leadership Change

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced that Aoife Brennan, M.B., B.Ch., has accepted the position of Interim President and Chief Executive Officer of Synlogic, effective immediately. This appointment follows the resignation of Jose Carlos Gutiérrez-Ramos, Ph.D., as Synlogic’s President and Chief Executive Officer and a member of its board of directors.

  • Business Wire5 months ago

    Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic™ medicine for the Treatment of Phenylketonuria

    Synlogic , a clinical-stage company applying synthetic biology to probiotic bacteria to develop novel living medicines, announced that the U.S. Food and Drug Administration has granted Fast Track designation to its clinical product candidate, SYNB1618.

  • Business Wire5 months ago

    Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria

    Synlogic (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to probiotic bacteria to develop novel living medicines, announced that it has dosed the first subject in its Phase 1/2a clinical trial of SYNB1618. SYNB1618 is a Synthetic Biotic medicine being developed for the treatment of phenylketonuria (PKU), a genetic disorder that results in decreased metabolism and accumulation of the amino acid phenylalanine (Phe), which can lead to seizures and cognitive impairment if not appropriately managed. Patients living with PKU currently have limited treatment options and endure a very restrictive diet that is low in protein, the source of dietary Phe.

  • Business Wire5 months ago

    Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting

    Synlogic, Inc.  , a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that preclinical data from its immuno-oncology program were featured in two presentations at the annual meeting of the American Association for Cancer Research .

  • Business Wire6 months ago

    Synlogic Announces Registered Direct Offering of Common Stock

    Synlogic, Inc. , a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has agreed to sell 3,280,000 shares of its common stock to a large mutual fund investor in a registered direct offering.

  • ACCESSWIRE6 months ago

    Wired News – Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis

    Stock Monitor: Ascendis Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 04, 2018 / Active-Investors.com has just released a free research report on Synlogic, Inc. (NASDAQ: SYBX ). If you ...

  • Business Wire6 months ago

    Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis

    Synlogic , a clinical-stage company applying synthetic biology to probiotic bacteria to develop novel living medicines, announced that the first patient was dosed in its Phase 1b/2a clinical trial of SYNB1020.

  • Business Wire6 months ago

    Synlogic to Present at the 17th Annual Needham Healthcare Conference

    Synlogic announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present a corporate update at the 17th Annual Needham Healthcare Conference at 12:15 p.m.

  • Associated Press6 months ago

    Mirna Therapeutics reports 4Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 74 cents. The biopharmaceutical company posted revenue of $111,000 in the period. For the year, the company reported ...

  • Business Wire6 months ago

    Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

    Synlogic, Inc. , a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today reported its financial results for the fourth quarter and full year ended December 31, 2017.

  • Business Wire6 months ago

    Synlogic to Present Data at the American Association for Cancer Research 2018 Annual Meeting

    Synlogic, Inc.,  a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that preclinical data from its immuno-oncology program will be presented at the upcoming annual meeting of the American Association for Cancer Research being held April 14 to 16, 2018, in Chicago.